Klinik fanlar yilnomasi 3-jild 2-son (2026)

CLINICAL, IMMUNOLOGICAL AND GENETIC RESEARCH IN PATIENTS WITH DEVELOPMENTAL DEFECTS

Пулатова Ш.Х

Manbada oʻqish PDF

Annotatsiya

Cardiorenal syndrome (CRS), along with its associated conditions of chronic kidney disease (CKD) and heart failure (HF), remains one of the most pressing issues in global medicine today. The following statistical indicators are based on international and local data. According to statistics, on a global scale, approximately 30-50% of patients with heart failure also experience impaired renal function (cardiorenal syndrome). To achieve our objective, 156 patients with the pathology of "heart failure concurrent with chronic kidney disease," who were treated at the Bukhara branch of the Republican Specialized Scientific and Practical Medical Center for Emergency Medicine in 2025-2026, were included in this research study.

cardiorenal syndrome, chronic kidney disease, heart failure, clinical-immunological and genetic studyкардиоренальный синдром, хроническая болезнь почек, сердечная недостаточность, клинико-иммунологическое и генетическое изучениекардиоренал синдром, сурункали буйрак касаллиги, юрак етишмовчилиги, клинико- иммунологик ва генетик ўрганиш

Metadata manbasi: jurnal OAI-PMH arxivi · Sindex toʻliq matnni saqlamaydi, manbaga havola beradi.

Iqtibos olish

APA 7
Пулатова Ш.Х (2026). CLINICAL, IMMUNOLOGICAL AND GENETIC RESEARCH IN PATIENTS WITH DEVELOPMENTAL DEFECTS. Klinik fanlar yilnomasi, 3(2).
GOST R 7.0.5
Пулатова Ш.Х CLINICAL, IMMUNOLOGICAL AND GENETIC RESEARCH IN PATIENTS WITH DEVELOPMENTAL DEFECTS // Klinik fanlar yilnomasi. 2026. Т. 3. № 2.
BibTeX
@article{ш.х2026,
  author  = {Пулатова Ш.Х},
  title   = {CLINICAL, IMMUNOLOGICAL AND GENETIC RESEARCH IN PATIENTS WITH DEVELOPMENTAL DEFECTS},
  journal = {Klinik fanlar yilnomasi},
  year    = {2026},
  volume  = {3},
  number  = {2}
}
RIS
TY  - JOUR
AU  - Пулатова Ш.Х
TI  - CLINICAL, IMMUNOLOGICAL AND GENETIC RESEARCH IN PATIENTS WITH DEVELOPMENTAL DEFECTS
JO  - Klinik fanlar yilnomasi
PY  - 2026
VL  - 3
IS  - 2
ER  -